Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

C. S. Chim; S. K. Kumar; R. Z. Orlowski; G. Cook; P. G. Richardson; M. A. Gertz; S. Giralt; M. V. Mateos; X. Leleu; K. C. Anderson

doi:10.1038/s41375-019-0410-3

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

C. S. Chim, S. K. Kumar, R. Z. Orlowski, G. Cook, P. G. Richardson, M. A. Gertz, S. Giralt, M. V. Mateos, X. Leleu, K. C. Anderson

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Original language	English (US)
Pages (from-to)	1058-1059
Number of pages	2
Journal	Leukemia
Volume	33
Issue number	4
DOIs	https://doi.org/10.1038/s41375-019-0410-3
State	Published - Apr 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-019-0410-3

Cite this

Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2019). Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329). Leukemia, 33(4), 1058-1059. https://doi.org/10.1038/s41375-019-0410-3

Chim, CS, Kumar, SK, Orlowski, RZ, Cook, G, Richardson, PG, Gertz, MA, Giralt, S, Mateos, MV, Leleu, X & Anderson, KC 2019, 'Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)', Leukemia, vol. 33, no. 4, pp. 1058-1059. https://doi.org/10.1038/s41375-019-0410-3

@article{78c349f1a41349189e8bbfaac2448603,

title = "Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)",

abstract = "Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.",

author = "Chim, {C. S.} and Kumar, {S. K.} and Orlowski, {R. Z.} and G. Cook and Richardson, {P. G.} and Gertz, {M. A.} and S. Giralt and Mateos, {M. V.} and X. Leleu and Anderson, {K. C.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = apr,

day = "1",

doi = "10.1038/s41375-019-0410-3",

language = "English (US)",

volume = "33",

pages = "1058--1059",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Correction

T2 - Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

AU - Chim, C. S.

AU - Kumar, S. K.

AU - Orlowski, R. Z.

AU - Cook, G.

AU - Richardson, P. G.

AU - Gertz, M. A.

AU - Giralt, S.

AU - Mateos, M. V.

AU - Leleu, X.

AU - Anderson, K. C.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

AB - Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

UR - http://www.scopus.com/inward/record.url?scp=85062627472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062627472&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0410-3

DO - 10.1038/s41375-019-0410-3

M3 - Comment/debate

C2 - 30842604

AN - SCOPUS:85062627472

SN - 0887-6924

VL - 33

SP - 1058

EP - 1059

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this